Sun Pharma, Philogen join hands to commercialise skin cancer drug in Europe, Australia, New Zealand
The companies have come together to commercialise Philogen's speciality product Nidlegy, an anti-cancer biopharmaceutical currently in Phase III clinical trials, Sun Pharma said in a statement.